Table 3. PSA response to DES therapy.

PSA, prostate-specific antigen; DES, diethylstilbestrol; PFD, progression free duration; NA, not applicable.

Therapy	Median (range)
PSA at the start of therapy	68.45 ng/mL (4.48-1,639 ng/mL)
Follow-up months	13.6 (6.5-22)
Overall PSA response to DES	n (%)
Yes	78 (85.7%)
No	13 (14.3%)
Change in PSA%, median (range)	-55.52 (-99.9, +422)(
Overall PFD, median (range)	6.98 months (1.77–34.38)
PSA response to DES	n (%)	Median time to progression
≥50% PSA response	56 (61.5%)	8.96 months
<50% PSA response	22 (24.2%)	3.5 months
No response	13 (14.3%)	NA